Patient-Derived Xenograft Model Market Analysis and Forecast to 2035: Type, Product, Mice Models, Services, Application, End User, Technology

Patient-Derived Xenograft Model Market is anticipated to expand from $363.7 million in 2025 to $1,121.9 million by 2035, growing at a CAGR of approximately 12.1%. Rising Oncology Research & Drug Development Needs - High demand from pharmaceutical and biotech companies for predictive preclinical models drives growth. Companies seek diverse PDX models (solid tumors, hematologic cancers, pediatric cancers) for translational studies and therapy evaluation. For instance, Charles River offers 1,700+ PDX models covering 45+ cancer indications, supporting drug efficacy testing across multiple tumor types.

Availability of Specialized Models - The supply of PDX models is limited, particularly for low-passage tumors, rare cancer types, and humanized platforms. Challenges in sourcing donor tissue and successful engraftment restrict production capacity. For example, Crown Bioscience's HSC-PDX and Hera BioLabs' MiXeno(TM) PBMC-humanized models represent high-demand specialized models with limited availability.

Regulatory Compliance and Data Reliability - There is strong demand for PDX models that maintain high genetic and histological fidelity, provide reproducible results, and meet regulatory standards. Models with these attributes are preferred for IND-enabling studies and translational research. For instance, Oncodesign and Charles River offer fully characterized PDX models that ensure clinical relevance and regulatory compliance.

Technological Advancements and Automation - Adoption of AI, imaging technologies, and organoid-based in vitro assays is enhancing the predictive power and efficiency of PDX studies. For example, Charles River's AI-enabled virtual control groups and 3D organoid PDX platforms accelerate preclinical testing and reduce reliance on animal models.

Segment Overview

Based on tumor type, the patient-derived xenograft (PDX) model market is divided into Gastro-Intestinal Tumors, Respiratory Tumors, Gynecological Tumors, Hematological Malignancies, Central Nervous System Tumors, Dermatological Tumors, and Other Solid Tumors.

The respiratory tumor segment is one of the fastest-growing due to lung cancer's high global burden lung cancer was the most frequently diagnosed cancer worldwide in 2022 with about 2.48 million new cases and also the leading cause of cancer death.

This high incidence drives strong demand for PDX models in NSCLC research to study driver mutations and resistance mechanisms. For example, in 2024, UCL researchers deposited 44 NSCLC TRACERx PDX models via CancerTools.org, enabling studies on tumor evolution, heterogeneity, immune escape, and drug resistance, supporting the rising demand for translational PDX models in lung cancer.

The gastro-intestinal tumor segment also strongly contributes to PDX adoption, as colorectal cancer ranked third globally with approximately 1.93 million new cases in 2022 and pancreatic cancer had around 510,992 new cases, both representing substantial unmet clinical needs that benefit from PDX platforms that better preserve tumor heterogeneity than traditional models.

The Gastro-Intestinal tumor segment is driven by the growing availability of clinically relevant PDX models that enable high-fidelity preclinical testing. Key developments include Champions Oncology's gastric cancer PDXs, which preserve patient tumor biology, and Crown Bioscience's extensive GI PDX library, covering colorectal and gastric cancers.

Additionally, Charles River Laboratories' 2019 expansion of 79 GI PDX models and The Jackson Laboratory's clinically validated GI portfolio provide robust platforms for drug screening and biomarker research. These resources accelerate translational research, support precision oncology pipelines, and reinforce strong segment growth.

The hematological malignancies segment is driving PDX market growth due to the critical need for models that replicate human leukemia, lymphoma, and multiple myeloma biology. PDX platforms, such as the AML panels by Crown Bioscience (2017) and the extensive hematologic PDX collection at the Washington University PDX Development and Trial Center (2025, Siteman Cancer Center), enable preclinical drug testing, mechanism-of-resistance studies, and personalized therapy evaluation.

Geographical Overview

The North American patient-derived xenograft (PDX) model market is expanding due to the rapidly rising cancer burden and the corresponding demand for predictive, patient-relevant preclinical models. In 2024, the United States is projected to report approximately 2,001,140 new cancer cases and 611,720 cancer deaths, reflecting a record-high incidence driven by population aging, improved diagnostic coverage, and increased screening uptake, all of which enhance the need for more biologically faithful oncology research models.

The United States accounts for the largest share of the North American PDX model market, supported by its extensive biopharmaceutical research ecosystem, specialized contract research organizations (CROs), and strong oncology-focused R&D investments. According to the National Center for Science and Engineering Statistics (NCSES), in 2023, U.S. companies invested approximately $722 billion in R&D, including $43 billion (6%) in basic research and $110 billion (15%) in applied research, underscoring the sustained funding priorities that reinforce demand for translational platforms such as PDX models.

Asia-Pacific is expected to be the fastest-growing region during the forecast period. The Asia-Pacific patient-derived xenograft (PDX) model market is rapidly growing due to the region's high cancer burden and expanding oncology research. According to Pfizer, there are about 3.6 million males and 4.0 million females living with cancer in major Asian countries, with China alone accounting for 1.6 million males and 1.5 million females. China has established large PDX libraries for gastrointestinal, lung, liver, and esophageal cancers, accurately preserving tumor histology and drug response.

Japan utilizes the J-PDX Library, Fukushima Medical University, and universities like Kanazawa for breast cancer, leukemia, pancreatic cancer, and pediatric ALL, supporting personalized medicine and drug testing. India is emerging as a hub for PDX studies, with ACTREC developing models for TNBC and hormone receptor-positive breast cancer, TheraIndx providing PDX/CDX models, and Altogen Labs validating 10 lung cancer xenograft models in August 2024.

Australia uses PDX models at Children's Cancer Institute, MURAL, UNSW Sydney, WEHI, and Peter MacCallum Cancer Centre for prostate, breast, colorectal, and pediatric cancers. South Korea employs PDX models at CHA Bundang Medical Center and Yonsei University Severance Hospital for ovarian, gastric, and biliary tract cancers.

Singapore leverages NCCS, A*STAR IMCB, and NUS for liver and biliary tract cancers. Indonesia is developing PDX models for breast and other solid tumors to support translational research. Across the region, these initiatives reflect rising cancer prevalence and adoption of patient-relevant preclinical models, driving strong PDX demand.

Key Trends and Drivers

"Rising Outsourcing of PDX Models to CROs Accelerates Market Expansion -

increasing outsourcing of oncology preclinical research to contract research organizations (CROs) drive the market growth. As pharma and biotech pipelines widening in-house capacities and shifting sponsors toward partners with specialized PDX capabilities.

Outsourcing to CROs allows sponsors to access expertise, infrastructure, and scalable vivarium resources that many internal labs lack, while reducing costs and accelerating translational timelines. For example, InnoSer's oncology CRO services offer comprehensive PDX mouse models for evaluating therapeutic efficacy, enabling sponsors to recapitulate tumor heterogeneity and treatment responses in vivo.

Similarly, LIDE Biotech maintains one of the world's largest PDX biobanks with over 1,900+ models covering nearly 50 cancer types, providing outsourced partners access to diverse, well-characterized xenografts for drug screening and translational studies.

Strategic collaborations further illustrate this outsourcing trend for instance, in October, 2025, XenoSTART and Minerva Imaging expanded their decade-long partnership to deliver a fully integrated PDX-radiopharmaceutical drug development platform, combining XenoSTART's clinically annotated PDX repository with Minerva's molecular imaging, radionuclide therapy expertise, and CDMO capabilities to streamline discovery through clinical translation.

As complex preclinical studies become the default outsourcing strategy for oncology sponsors, CROs specializing in PDX models are achieving above-market growth, reinforcing regional leadership in hubs such as China, Singapore, and India and driving incremental demand across the global PDX models market.

Increasing Cancer Burden and Advanced Screening -

A key trend driving the global patient-derived xenograft (PDX) models market is the rising global cancer incidence coupled with advances in early detection technologies, which is intensifying demand for biologically relevant preclinical models. According to the World Health Organization (WHO), global cancer cases are projected to reach 35 million by 2050, a 77% increase from 20 million cases in 2022.

Similarly, In India, cancer cases have doubled since 1990, with 1.57 million new cases projected in 2025 and over 820,000 deaths in 2023, driven by tobacco and alcohol use, obesity, sedentary lifestyles, and environmental pollution. The most common cancers in these regions include breast, lung, colorectal, oral, and kidney cancers. Additionally, in the United States, 2,041,910 new cancer cases and 618,120 deaths are projected in 2025 (NIH, 2025), underscoring the ongoing need for predictive preclinical models.

The growing cancer burden is matched by advancements in early detection, including low-dose CT scans for lung cancer, digital breast tomosynthesis (3D mammography), and minimally invasive liquid biopsies that analyze circulating tumor DNA (ctDNA) or minimal residual disease (MRD). These technologies allow identification of tumors at earlier, more biologically diverse stages, expanding the range of tumors available for translational research.

Regions such as Asia-Pacific, the Middle East, and Africa are increasingly adopting PDX platforms to translate preclinical findings into precision oncology solutions, supported by public initiatives like ARPA-H's USD 25 million at-home multi-cancer screening program, which drives demand for xenografts to evaluate subtype-specific therapies. As cancer becomes more detectable, diverse, and clinically complex, accelerating the adoption of PDX models as essential tools in modern precision oncology research and drug development.

Research Scope

• Estimates and forecasts the overall market size across type, product, mice models, services, application, end user, technology, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.